Experts Discuss Relevant Endpoints in Multiple Myeloma Clinical Papers
Watch Dr. Evangelos Terpos and Dr. Nina Shah discuss why both progression-free survival (PFS) and minimal residual disease (MRD) are relevant endpoints to be aware of in clinical trials.
Exploring the True Cost of Multiple Myeloma
Despite more than a decade’s worth of research and data collection in the field of multiple myeloma, there still is a lack of an all-encompassing report and data that reflect the true cost of multiple myeloma. Explore a study highlighting the socioeconomic impact of multiple myeloma as well as the costs of treatments and hospital visits.
Early Diagnosis and Increased Incidence
As the incidence of multiple myeloma grows globally and most patients inevitably relapse, there is an unmet need to continue to improve outcomes in patients with RRMM.
The Increasing Importance of Minimal Residual Disease (MRD)
Better understand how MRD relates to progression-free survival (PFS) and overall survival (OS).
Helping High-Risk Subgroups With Multiple Myeloma
Learn how the continued underrepresentation of high-risk subgroups in clinical trials affects patient outcomes.
REFERENCE: 1. Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067-1076.